Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer ETNA (Evaluating Treatment with Neoadjuvant Abraxane)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Cyclophosphamide; Doxorubicin; Epirubicin; Fluorouracil
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms ETNA
- 04 Jun 2019 Results from an event-free survival analysis (secondary outcome) of this trial, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 31 Aug 2018 Biomarkers information updated
- 21 Apr 2017 Planned End Date changed from 1 Oct 2025 to 31 Dec 2025.